Overview

Split-course Thoracic Radiotherapy Combined With Nab-paclitaxel Plus Nedaplatin for Local Advanced NSCLC With Impaired Baseline Pulmonary Function

Status:
Recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

This Phase II randomized study is to determine the efficacy of split-course thoracic radiotherapy combined with nab-paclitaxel plus nedaplatin for local advanced non-small cell lung cancer with severe impairment of baseline pulmonary function.

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Albumin-Bound Paclitaxel
Nedaplatin
Paclitaxel